Drugs Containing Excipient (Inactive Ingredient) BENZALDEHYDE

Generic drugs containing BENZALDEHYDE excipient

Company	Ingredient	NDC	Excipient
L Perrigo Company	nicotine polacrilex	0113-7007	BENZALDEHYDE
L Perrigo Company	nicotine polacrilex	0113-7020	BENZALDEHYDE
L Perrigo Company	nicotine polacrilex	0113-7031	BENZALDEHYDE

Benzaldehyde Excipient Market Dynamics, Pricing, Supply Chain, and Financial Outlook

Last updated: September 9, 2026

Benzaldehyde is a low-volume pharmaceutical excipient and a much larger industrial chemical used in flavors, fragrances, agrochemicals, resins, and pharmaceutical synthesis. Its pharmaceutical value comes mainly from flavoring and odor-masking in oral products, while most global demand is generated outside finished-dose medicines. The market has commodity-like economics: feedstock costs, plant utilization, Chinese supply, quality certification, logistics, and regulatory compliance have greater influence on margins than pharmaceutical innovation.

No major standalone drug exclusivity, Orange Book listing, Paragraph IV dispute, or biosimilar issue applies to benzaldehyde as an excipient. Commercial risk is concentrated in supplier qualification, impurity control, supply continuity, and price volatility.

What is benzaldehyde and how is it used in pharmaceutical products?

Benzaldehyde is an aromatic aldehyde with the following core specifications:

Attribute	Data
Chemical name	Benzaldehyde
CAS number	100-52-7
Molecular formula	C7H6O
Molecular weight	106.12 g/mol
Physical form	Clear, colorless to pale-yellow liquid
Primary pharmaceutical role	Flavoring and odor-masking agent
Major non-pharmaceutical roles	Flavor, fragrance, agrochemical and pharmaceutical intermediate
Main degradation concern	Oxidation to benzoic acid
Typical handling concern	Volatile, combustible liquid with strong odor

In medicines, benzaldehyde is most relevant to oral liquids, chewable products, orally disintegrating dosage forms, and other products where taste and odor affect patient acceptance. It is generally used at low concentrations. The pharmaceutical-grade market is therefore small relative to the total benzaldehyde market.

Benzaldehyde is also an intermediate in the manufacture of active pharmaceutical ingredients, fine chemicals, fragrances, dyes, and crop-protection compounds. Those applications can consume materially greater volumes than finished pharmaceutical formulations.

What is the FDA regulatory status of benzaldehyde as an excipient?

Benzaldehyde is regulated primarily as a flavoring substance and chemical ingredient rather than as an active pharmaceutical ingredient. Its regulatory treatment depends on use, concentration, route of administration, product type, and jurisdiction.

The principal U.S. regulatory considerations are:

Regulatory issue	Status
FDA drug active ingredient	Not applicable
FDA inactive ingredient	Relevant where listed for the specific dosage form and route
Food flavoring status	Benzaldehyde is recognized as a flavoring substance under U.S. food regulations and FEMA listings
New drug exclusivity	Not applicable to the excipient itself
Orange Book listing	No standalone Orange Book listing expected
Paragraph IV litigation	No ordinary Paragraph IV pathway for benzaldehyde as an excipient
Biosimilar exposure	Not applicable
GMP expectations	Apply when supplied for pharmaceutical manufacturing
Pharmacopoeial status	Relevant where the buyer requires USP-NF, Ph. Eur., or another compendial grade

FDA’s Inactive Ingredient Database is the practical reference for prior use in approved drug products. The database does not create market exclusivity. It provides regulatory precedent and helps manufacturers assess whether a proposed level and route have been used in approved products.[1]

For pharmaceutical buyers, a flavor-grade material is not automatically equivalent to a pharmaceutical-grade material. The supplier must support identity, assay, impurity profile, residual solvents, elemental impurities, packaging compatibility, stability, and change-control documentation.

How large is the benzaldehyde excipient market?

The standalone pharmaceutical-excipient segment is not reported consistently in public market studies. Most commercial reports combine benzaldehyde used in flavors, fragrances, pharmaceuticals, agrochemicals, and industrial synthesis. This makes headline market-size estimates poor measures of pharmaceutical demand.

The economic hierarchy is more useful than a single market-size number:

1. Industrial and chemical-intermediate demand represents the largest volume pool.
2. Flavor and fragrance demand provides a significant recurring outlet.
3. Pharmaceutical finished-product use is a smaller, higher-specification niche.
4. Pharmaceutical intermediate use can exceed excipient use for certain supply chains.

The excipient segment has limited ability to move the global benzaldehyde price because pharmaceutical consumption is small compared with total industrial demand. However, drug manufacturers pay a premium for:

• Pharmacopeial compliance
• Validated analytical methods
• Consistent impurity control
• GMP manufacturing
• Auditable supply chains
• Dual sourcing
• Stability data
• Controlled change notification

This creates a two-tier market. Bulk industrial benzaldehyde competes mainly on cost and availability. Pharmaceutical-grade benzaldehyde competes on total quality cost and regulatory reliability.

What drives benzaldehyde demand?

Flavors and fragrances

Benzaldehyde has an almond-like odor and flavor profile. It is used directly in flavor systems and as a building block for fragrance chemicals. Consumer products, confectionery, beverages, oral-care products, and pharmaceutical flavors support this demand.

Pharmaceutical and fine-chemical synthesis

Benzaldehyde is a versatile aromatic intermediate. It can be converted into benzyl alcohol, benzoic acid, benzoin derivatives, imines, oximes, and other intermediates. Demand is linked to the production of APIs, specialty chemicals, and research compounds.

Agrochemicals

Benzaldehyde participates in the manufacture of crop-protection intermediates. Agricultural chemical demand can create a larger and more cyclical demand source than pharmaceutical excipient use.

Industrial materials

Applications include dyes, resins, coatings, and specialty organic synthesis. These markets are sensitive to construction, manufacturing, and export conditions.

How is benzaldehyde manufactured and what are the supply risks?

Commercial benzaldehyde is produced through several routes. The principal industrial route is controlled oxidation of toluene. Other routes include chlorination of toluene followed by hydrolysis, and specialty routes based on other aromatic intermediates.

Manufacturing factor	Commercial effect
Toluene price	Direct feedstock influence
Oxidation selectivity	Determines yield and benzoic-acid formation
Plant utilization	Affects fixed-cost absorption
Chinese capacity	Influences global availability and spot pricing
Energy costs	Affect oxidation, separation, and distillation
Logistics	Benzaldehyde is a hazardous liquid requiring suitable packaging
Product stability	Oxidation and discoloration can cause rejected lots
Regulatory documentation	Raises cost for pharmaceutical-grade supply

The main technical challenge is controlling oxidation. Benzaldehyde can oxidize to benzoic acid during manufacture, storage, or handling. Buyers commonly monitor assay, acidity, benzyl alcohol, color, water, nonvolatile residue, and related aromatic impurities. Packaging, headspace, temperature, and exposure to air can affect shelf life.

Supply concentration creates a larger risk than pharmaceutical patent protection. A drug manufacturer may qualify a material from one supplier but still face a replacement delay if the supplier changes its process, site, raw-material source, specification, or packaging.

Which companies supply benzaldehyde for pharmaceutical and industrial use?

The market includes large specialty-chemical companies, regional manufacturers, and laboratory distributors. Representative supplier categories include:

Supplier category	Typical position
Large specialty-chemical manufacturers	Bulk production, global quality systems, long-term supply
Regional Asian producers	Cost-competitive bulk and intermediate supply
Flavor and fragrance companies	Formulation expertise and flavor-grade distribution
Laboratory distributors	Small-volume, high-price research and development supply
Contract manufacturers	Customer-specific grades, packaging, and documentation

LANXESS, through the Emerald Kalama Chemical business, is a recognized participant in specialty chemicals and flavor-related materials, including benzaldehyde-related products.[2] Other suppliers operate regionally across China, India, Europe, and North America. Distributor listings do not necessarily indicate manufacturing capacity or pharmaceutical-grade qualification.

A buyer should distinguish between:

• Manufacturer and reseller status
• Food-grade, technical-grade, and pharmaceutical-grade material
• Site-specific GMP certification
• Compendial compliance
• Batch-release testing
• Regulatory-support package
• Continuity of supply
• Change-control obligations

How does benzaldehyde pricing affect the financial trajectory?

Benzaldehyde pricing is determined primarily by feedstock and capacity conditions rather than by pharmaceutical demand. The financial trajectory is therefore cyclical and margin-sensitive.

Revenue trajectory

Demand should remain stable to moderately growing where supported by:

• Oral pharmaceutical products requiring flavor systems
• Fragrance and flavor consumption
• API and fine-chemical synthesis
• Agricultural chemical production
• Emerging-market manufacturing

The pharmaceutical excipient portion should grow more slowly than the broader chemical market unless oral dosage-form development increases materially.

Margin trajectory

Margins are likely to separate by grade:

Product position	Margin characteristics
Technical grade	Low to moderate; price-driven
Food or flavor grade	Moderate; documentation and sensory consistency add value
Pharmaceutical grade	Higher gross margin potential, but higher compliance and testing costs
Custom or validated supply	Stronger customer retention and pricing discipline
Laboratory pack	High unit margin, low volume

Pharmaceutical-grade supply does not automatically produce high returns. Qualification costs, audits, batch testing, inventory requirements, and customer-specific documentation can absorb much of the nominal price premium.

Working-capital exposure

Benzaldehyde suppliers carry several working-capital burdens:

• Inventory required to support dual-region supply
• Hazardous-goods storage
• Packaging and transport controls
• Slow-moving pharmaceutical-grade stock
• Separate lots for customers with different specifications
• Retention samples and quality records

A supplier with high pharmaceutical exposure may earn better customer retention but carry more inventory and quality overhead than a supplier focused on commodity sales.

What patents protect benzaldehyde and its pharmaceutical uses?

The underlying benzaldehyde molecule is long established. Basic composition-of-matter protection is expired and does not create current exclusivity.

Potentially relevant patent categories include:

Patent category	Current commercial relevance
Benzaldehyde composition patent	No meaningful current exclusivity
Manufacturing process patent	May protect a particular oxidation or purification process
Catalyst patent	May affect plant economics but usually does not block all supply
Pharmaceutical formulation patent	Could cover a specific drug product containing benzaldehyde
Flavor-system patent	May protect a broader formulation, not benzaldehyde itself
API-intermediate process patent	May affect downstream customers
Packaging or stabilization patent	Usually narrow and product-specific

A process patent may create an advantage in yield, purity, energy consumption, or impurity control. It does not necessarily prevent competitors from making benzaldehyde through a different route.

What is the Orange Book status of benzaldehyde?

Benzaldehyde is not expected to have a standalone Orange Book listing because it is not marketed as an FDA-approved active drug product with independent therapeutic labeling. Orange Book patents are associated with approved drug products, not ordinary excipients sold into pharmaceutical manufacturing.[3]

Are there Paragraph IV challenges involving benzaldehyde?

There is no standard Paragraph IV framework for benzaldehyde as a standalone excipient. Paragraph IV certifications address patents listed for approved drug products in abbreviated new drug applications. A generic drug containing benzaldehyde as a flavoring agent would challenge the drug product’s listed patents, if any, rather than patents covering benzaldehyde as a chemical commodity.[4]

What formulation and method-of-use patents could affect benzaldehyde?

Benzaldehyde can appear in patent claims covering:

• Taste-masked oral formulations
• Flavor systems
• Liquid dosage forms
• Chewable tablets
• Orally disintegrating tablets
• Combination products
• Stabilized aromatic compositions
• Manufacturing processes for a specific API

These rights usually belong to the drug-product developer, not the excipient producer. A formulation patent may restrict a competitor’s use of benzaldehyde in a particular product without restricting general sale of benzaldehyde.

Method-of-use patents are similarly product-specific. Benzaldehyde itself has no recognized therapeutic use comparable to an active pharmaceutical ingredient. Any enforceable use claim would depend on a particular formulation, treatment method, or chemical process.

What licensing deals and settlement agreements affect benzaldehyde?

There is no prominent industry-wide licensing structure comparable to the licensing markets for patented APIs, biologics, or drug-delivery platforms. Commercial arrangements are more commonly:

• Supply agreements
• Quality agreements
• Toll-manufacturing contracts
• Regional distribution agreements
• Private-label arrangements
• Technology licenses for oxidation or purification
• Customer-specific exclusivity commitments

Settlement agreements are unlikely to affect commodity benzaldehyde supply broadly. If litigation exists, it is more likely to concern a manufacturing process, a downstream formulation, trade secrets, or a particular customer contract.

What generic entry risks exist for medicines containing benzaldehyde?

Generic entry risk is determined by the active pharmaceutical ingredient and the finished dosage form, not by benzaldehyde. Benzaldehyde can influence product differentiation in three ways:

1. A branded product may use a proprietary flavor system.
2. A formulation patent may claim a specific excipient combination.
3. A generic applicant may need to match taste, odor, stability, or inactive-ingredient precedent.

These factors can raise development costs but rarely create durable exclusivity for benzaldehyde itself. The principal generic risks remain active-ingredient patents, formulation patents, method-of-use patents, regulatory exclusivity, and manufacturing complexity.

How does benzaldehyde compare with competing pharmaceutical flavoring agents?

Attribute	Benzaldehyde	Vanillin	Ethyl vanillin	Menthol
Primary sensory profile	Almond/cherry	Vanilla	Strong vanilla	Cooling/minty
Physical form	Liquid	Solid	Solid	Solid or crystalline
Main formulation role	Flavor and odor masking	Flavor masking	High-intensity flavor	Cooling and flavor
Oxidation concern	Relatively important	Lower volatility	Lower volatility	Stability and sublimation concerns
Handling	Volatile liquid	Powder or crystals	Powder or crystals	Crystalline
Supply economics	Commodity aromatic liquid	Broad flavor market	Higher-value flavor	Large flavor and topical market
Pharmaceutical differentiation	Limited	Limited to moderate	Limited to moderate	Moderate in oral and topical products

Benzaldehyde’s liquid form can simplify certain flavor systems but can complicate packaging, volatility control, and oxidation management. Vanillin and ethyl vanillin are often easier to handle as dry ingredients but may produce different sensory outcomes and require different formulation levels.

What geographic markets matter most?

China

China is central to global aromatic chemical capacity and can materially affect pricing, availability, and export competition. Environmental enforcement, energy costs, plant shutdowns, and domestic demand can change regional supply rapidly.

India

India has growing pharmaceutical, flavor, fragrance, and specialty-chemical manufacturing capacity. Indian demand is supported by API production and domestic formulation growth.

Europe

Europe remains important for regulated supply, specialty chemicals, flavors, and pharmaceutical manufacturing. Energy costs and environmental compliance can raise production costs relative to some Asian suppliers.

United States

The U.S. is a major pharmaceutical and flavor market, with demand concentrated in downstream formulation, distribution, and regulated supply. Domestic production and imports both contribute to availability.

Japan and South Korea

These markets emphasize high-purity chemicals, advanced manufacturing, and long-term supplier qualification. Volumes are smaller than in broader industrial markets but can support higher specification requirements.

How strong is the benzaldehyde patent estate?

The patent estate is weak for the molecule and potentially meaningful for selected manufacturing or downstream formulation technologies.

Estate component	Strength
Core molecule	Very weak; historic protection expired
Bulk manufacturing	Moderate only for narrow process claims
Purification and impurity control	Potentially useful but design-around risk is high
Pharmaceutical excipient use	Limited
Drug-specific formulations	Potentially strong, but product-specific
Trade secrets	Can be commercially important at the plant level
Regulatory know-how	Relevant to supplier switching, not exclusivity

The most durable competitive barriers are likely to be process know-how, validated quality systems, customer qualification, reliable logistics, and scale.

What is the commercial outlook for benzaldehyde excipient suppliers?

The base-case outlook is stable rather than high-growth. Revenue should track broader demand in flavors, fragrances, pharmaceuticals, agrochemicals, and fine chemicals. Pharmaceutical-grade suppliers can improve economics through qualification support, regional inventory, dual sourcing, and validated quality packages.

Key upside drivers include:

• Growth in oral liquid and pediatric medicines
• Expansion of flavor and fragrance consumption
• Higher demand for regulated pharmaceutical excipients
• Supply-chain diversification away from single-country sourcing
• Increased use of specialty-grade materials

Key downside drivers include:

• Toluene and energy-price increases
• Excess Chinese capacity
• Substitution by other flavoring agents
• Weak agrochemical or industrial demand
• Customer reformulation
• Regulatory rejection caused by impurity or documentation failures
• Plant shutdowns and transport restrictions

For investors, benzaldehyde is best analyzed as part of a diversified specialty-chemical portfolio, not as a standalone pharmaceutical growth asset. For drug manufacturers, the main financial issue is business interruption and reformulation cost, not excipient price. Benzaldehyde typically represents a small percentage of finished-product cost but can create disproportionate operational exposure if a qualified source is lost.

Key Takeaways

• Benzaldehyde is a small pharmaceutical excipient market embedded in a much larger industrial chemical market.
• Its principal pharmaceutical role is flavoring and odor masking in oral dosage forms.
• The molecule has no meaningful current composition-of-matter exclusivity.
• Standalone Orange Book, Paragraph IV, biosimilar, and drug-exclusivity issues generally do not apply.
• Manufacturing economics depend on toluene, energy, plant utilization, oxidation selectivity, and Chinese supply.
• Pharmaceutical-grade premiums arise from GMP systems, impurity control, documentation, and supply reliability.
• The most important barriers are supplier qualification, validated processes, and quality consistency.
• Revenue growth should be moderate and diversified across flavors, fragrances, agrochemicals, pharmaceuticals, and fine chemicals.
• Drug developers face low direct cost exposure but potentially high switching and interruption costs.
• The patent estate is weak for the molecule and narrower, process-specific, or downstream for commercial applications.

FAQs

Is benzaldehyde safe as a pharmaceutical excipient?

Safety depends on concentration, route, product formulation, impurity profile, and applicable regulatory precedent. Pharmaceutical use requires a documented safety and quality assessment rather than reliance on food-flavoring status alone.

Is benzaldehyde listed in the FDA Inactive Ingredient Database?

Benzaldehyde should be assessed through the FDA Inactive Ingredient Database for the intended route and dosage form. An IID entry indicates prior approved use; it does not approve every concentration or formulation.[1]

Can benzaldehyde be replaced by vanillin in a drug formulation?

Replacement is technically possible in some flavor systems but requires sensory, stability, compatibility, regulatory, and potentially bioequivalence assessment. The two materials have different physical properties and flavor profiles.

Does benzaldehyde require pharmaceutical GMP manufacturing?

A supplier serving regulated drug manufacturing is generally expected to operate under appropriate quality systems and provide documentation consistent with the customer’s GMP and regulatory obligations. The exact standard depends on the product and jurisdiction.

What is the main investment risk in benzaldehyde?

The main risk is commodity-cycle exposure combined with supplier concentration. Feedstock volatility, oversupply, environmental restrictions, plant outages, and weak industrial demand can affect margins more than pharmaceutical excipient demand.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. LANXESS AG. (n.d.). Emerald Kalama Chemical and specialty chemicals portfolio. https://www.lanxess.com
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and Paragraph IV patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submissions